Inhibrx Inc (INBX)
34.11
-0.27
(-0.79%)
USD |
NASDAQ |
Apr 25, 16:00
34.11
0.00 (0.00%)
After-Hours: 20:00
Inhibrx Cash from Investing (TTM): -4.593M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -4.593M |
| September 30, 2023 | -1.418M |
| June 30, 2023 | -0.587M |
| March 31, 2023 | -0.592M |
| December 31, 2022 | -0.686M |
| September 30, 2022 | -0.686M |
| June 30, 2022 | -0.875M |
| March 31, 2022 | -0.912M |
| December 31, 2021 | -0.809M |
| September 30, 2021 | -1.154M |
| Date | Value |
|---|---|
| June 30, 2021 | -1.284M |
| March 31, 2021 | -1.287M |
| December 31, 2020 | -1.364M |
| September 30, 2020 | -1.087M |
| June 30, 2020 | -1.499M |
| March 31, 2020 | -1.824M |
| December 31, 2019 | -1.81M |
| September 30, 2019 | -1.986M |
| June 30, 2019 | -1.35M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-4.593M
Minimum
Dec 2023
-0.587M
Maximum
Jun 2023
-1.358M
Average
-1.284M
Median
Jun 2021
Cash from Investing (TTM) Benchmarks
| Johnson & Johnson | 878.00M |
| Gilead Sciences Inc | -2.265B |
| Outlook Therapeutics Inc | -- |
| Axonics Inc | -116.90M |
| NovaBay Pharmaceuticals Inc | -0.019M |